Cancer
Malignant Pancreatic Neoplasm
CI-CAN-00001159Explore in graph →
Top-level904 active trials8 approved drugs63 evidence items
- NCIt
- C9005
- ICD-10
- C25
- DOID
- 1793
- Other
- 1 more code
Loading cancer entity…
Loading cancer entity…
Cancer
CI-CAN-00001159Explore in graph →
Clinical trials
3,630 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (516)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02620865 | BATS With in Combination With Low Dose IL-1 and GM-CSF for Advanced Pancreatic Cancer | completed | Phase 1 / Phase 2 | 2 | Barbara Ann Karmanos Cancer InstituteOTHER | 1 | May 15, 2023 | clinicaltrials |
| NCT01845337 | Study to Compare Cardiovascular Side Effects of Teysuno Versus Capecitabine(TOFFEE) | completed | Phase 2 | 59 | University of EdinburghOTHER | 1 | May 12, 2023 | clinicaltrials |
| NCT01420874 | Anti-CD3 x Anti-Erbitux® Armed Activated T Cells (Phase Ib) for Gastrointestinal (GI Cancer) | completed | Phase 1 | 15 | Barbara Ann Karmanos Cancer InstituteOTHER | 1 | May 6, 2023 | clinicaltrials |
| NCT02578732 | FOLFOX-A For Locally Advanced Pancreatic Cancer: A Phase II Brown University Oncology Research Group Trial | completed | Phase 2 | 28 | Brown UniversityOTHER | 1 | May 6, 2023 | clinicaltrials |
| NCT03126435 | EndoTAG-1+GEM vs GEM in Patients With Locally Advanced/Metastatic Pancreatic Adenocarcinoma Failed on FOLFIRINOX | completed | Phase 3 | 218 | SynCore Biotechnology Co., Ltd.INDUSTRY | 7 | May 6, 2023 | clinicaltrials |
| NCT03821870 | Predictive Value of Analysing Tissue From Patients With Metastatic Pancreatic Cancer for Drug Sensitivity(TIP) | completed | — | 12 | Vejle HospitalOTHER | 1 | May 1, 2023 | clinicaltrials |
| NCT03841110 | FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors | completed | Phase 1 | 37 | Fate TherapeuticsINDUSTRY | 1 | May 1, 2023 | clinicaltrials |
| NCT03961646 | Evaluation of the FOCUS Diffusion's Added Clinical Value Compared to Conventional MRI | completed | — | 74 | Fondation Hôpital Saint-JosephOTHER | 1 | Apr 28, 2023 | clinicaltrials |
| NCT02853474 | Early Palliative Care in Patients With Metastatic Upper Gastrointestinal Cancers Treated With First-line Chemotherapy(EPIC-1511) | completed | Phase 3 | 480 | Centre Oscar LambretOTHER | 1 | Apr 26, 2023 | clinicaltrials |
| NCT02194829 | Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Gemcitabine Hydrochloride With or Without WEE1 Inhibitor AZD1775 in Treating Patients With Previously Untreated Pancreatic Cancer That Is Metastatic or Cannot Be Removed by Surgery | completed | Phase 1 / Phase 2 | 8 | National Cancer Institute (NCI)NIH | 1 | Apr 25, 2023 | clinicaltrials |
| NCT02511223 | Efficacy and Safety of PARPi to Treat Pancreatic Cancer(10) | completed | Phase 2 | 24 | Sheba Medical CenterOTHER_GOV | 1 | Apr 19, 2023 | clinicaltrials |
| NCT01774019 | Preoperative Biliary Drainage in Resectable Pancreatic or Periampullary Cancer | completed | N/A | 284 | Boston Scientific CorporationINDUSTRY | 9 | Apr 10, 2023 | clinicaltrials |
| NCT02806687 | Effect of Intratumoral Injection of Gene Therapy for Locally Advanced Pancreatic Cancer(THERGAP-02) | completed | Phase 2 | 68 | University Hospital, ToulouseOTHER | 1 | Mar 30, 2023 | clinicaltrials |
| NCT03849469 | A Study of XmAb®22841 Monotherapy & in Combination w/ Pembrolizumab in Subjects w/ Selected Advanced Solid Tumors(DUET-4) | completed | Phase 1 | 78 | Xencor, Inc.INDUSTRY | 1 | Mar 30, 2023 | clinicaltrials |
| NCT04236102 | KEBI-Cyto Study - Use of the Biocartis Idylla | completed | N/A | 55 | Royal Cornwall Hospitals TrustOTHER | 1 | Mar 29, 2023 | clinicaltrials |
| NCT03717298 | Evaluation of Ocoxin-Viusid® in Advanced Pancreatic Adenocarcinoma | completed | Phase 2 | 30 | Catalysis SLINDUSTRY | 1 | Mar 28, 2023 | clinicaltrials |
| NCT03801915 | Perioperative MVT-5873, a Fully Human Monoclonal Antibody Against a CA 19-9 Epitope, for Operable CA 19-9 Producing Pancreatic Cancers, Cholangiocarcinomas, and Metastatic Colorectal Cancers | completed | Phase 2 | 10 | National Cancer Institute (NCI)NIH | 1 | Mar 21, 2023 | clinicaltrials |
| NCT03507452 | First-in-human Study of BAY2287411 Injection, a Thorium-227 Labeled Antibody-chelator Conjugate, in Patients With Tumors Known to Express Mesothelin | completed | Phase 1 | 36 | BayerINDUSTRY | 5 | Mar 20, 2023 | clinicaltrials |
| NCT01129167 | Frequency of Methods of Local Invasion of Pancreatic Adenocarcinoma | completed | — | 1,052 | Columbia UniversityOTHER | 1 | Mar 17, 2023 | clinicaltrials |
| NCT02707159 | Circulating Tumor Cells as Tools for Therapy Response in Nab-paclitaxel Treated Metastatic Pancreatic Cancer Patients(PACT-ACT-v6) | completed | Phase 2 | 70 | Helse Stavanger HFOTHER_GOV | 1 | Mar 8, 2023 | clinicaltrials |
| NCT02210559 | A Study of Gemcitabine Plus Nab-paclitaxel With or Without FG-3019 in Participants With Locally Advanced, Unresectable Pancreatic Cancer | completed | Phase 1 / Phase 2 | 37 | Kyntra BioINDUSTRY | 1 | Mar 2, 2023 | clinicaltrials |
| NCT03998566 | Radiopaque Hydrogel Spacer in Patients Undergoing Radiotherapy for Pancreatic Cancer | completed | N/A | 6 | Boston Scientific CorporationINDUSTRY | 1 | Feb 27, 2023 | clinicaltrials |
| NCT03871959 | Pembrolizumab In Combination With Debio 1143 In Pancreatic and Colorectal Advanced/Metastatic Adenocarcinoma(CATRIPCA) | completed | Phase 1 | 54 | Centre Leon BerardOTHER | 1 | Feb 17, 2023 | clinicaltrials |
| NCT02028806 | mFOLFIRINOX as First-Line Chemotherapy in Treating Chinese Patients With Metastatic Pancreatic Cancer | completed | Phase 2 | 40 | Yuhong LiOTHER | 1 | Feb 16, 2023 | clinicaltrials |
| NCT01647828 | A Phase 1b/2 Study of OMP-59R5 (Tarextumab) in Combination With Nab-Paclitaxel and Gemcitabine in Subjects With Previously Untreated Stage IV Pancreatic Cancer(ALPINE) | completed | Phase 1 / Phase 2 | 217 | OncoMed Pharmaceuticals, Inc.INDUSTRY | 1 | Feb 15, 2023 | clinicaltrials |
| NCT04542291 | Targeting Pancreatic Cancer With Sodium Glucose Transporter 2 (SGLT2) Inhibition | completed | Phase 1 | 15 | Washington University School of MedicineOTHER | 1 | Feb 14, 2023 | clinicaltrials |
| NCT03871790 | Peptide-based Immunization for Colon- and and Pancreas-carcinoma(PICOP-GLOBAL) | completed | — | 50 | CENTOGENE GmbH RostockINDUSTRY | 1 | Feb 10, 2023 | clinicaltrials |
| NCT02930902 | Pembrolizumab and Paricalcitol With or Without Chemotherapy in Patients With Pancreatic Cancer That Can Be Removed by Surgery | completed | Phase 1 | 9 | M.D. Anderson Cancer CenterOTHER | 1 | Feb 9, 2023 | clinicaltrials |
| NCT03977272 | Combination of Anti-PD-1 Antibody and Chemotherapy in Metastatic Pancreatic Cancer | completed | Phase 2 | 110 | Zhejiang UniversityOTHER | 1 | Jan 27, 2023 | clinicaltrials |
| NCT04476082 | Nutrition in Gastrointestinal Tumors(NutriGIT) | completed | — | 66 | University Medicine GreifswaldOTHER | 1 | Jan 25, 2023 | clinicaltrials |
| NCT02713529 | Safety and Efficacy Study of AMG 820 and Pembrolizumab Combination in Select Advanced Solid Tumor Cancer | completed | Phase 1 / Phase 2 | 117 | AmMax Bio, Inc.INDUSTRY | 6 | Jan 20, 2023 | clinicaltrials |
| NCT04430842 | Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of QBS10072S | completed | Phase 1 | 15 | Quadriga Biosciences, Inc.INDUSTRY | 1 | Jan 18, 2023 | clinicaltrials |
| NCT02948309 | Mistletoe Therapy in Primary and Recurrent Inoperable Pancreatic Cancer(MISTRAL) | completed | Phase 3 | 290 | Karolinska University HospitalOTHER | 1 | Jan 13, 2023 | clinicaltrials |
| NCT01774643 | A Study of Pancreatic Cancer in Xenografts From Liver Metastases | completed | — | 31 | University Health Network, TorontoOTHER | 1 | Jan 10, 2023 | clinicaltrials |
| NCT03331562 | A SU2C Catalyst® Trial of a PD1 Inhibitor With or Without a Vitamin D Analog for the Maintenance of Pancreatic Cancer | completed | Phase 2 | 24 | Translational Genomics Research InstituteOTHER | 1 | Dec 27, 2022 | clinicaltrials |
| NCT01939665 | PANFIRE Study: Irreversible Electroporation (IRE) to Treat Locally Advanced Pancreatic Carcinoma(PANFIRE) | completed | Phase 1 / Phase 2 | 50 | Amsterdam UMC, location VUmcOTHER | 1 | Dec 20, 2022 | clinicaltrials |
| NCT02873598 | A Dose Escalation Trial of SBRT After Induction Chemotherapy for Locally Advanced Pancreatic Cancer | completed | Phase 1 | 14 | University of Colorado, DenverOTHER | 1 | Dec 19, 2022 | clinicaltrials |
| NCT04080024 | A First-in-human Clinical Evaluation of SN132D in Patients With Breast and Pancreatic Cancer(SPAGOPIX-01) | completed | Phase 1 | 14 | Spago Nanomedical ABINDUSTRY | 1 | Dec 9, 2022 | clinicaltrials |
| NCT02564146 | First-line Treatment of Metastatic Pancreatic Cancer With Nab-paclitaxel and Gemcitabine(ALPACA) | completed | Phase 2 | 325 | AIO-Studien-gGmbHOTHER | 1 | Nov 22, 2022 | clinicaltrials |
| NCT02810652 | Perioperative Geriatrics Intervention for Older Cancer Patients Undergoing Surgical Resection | completed | N/A | 160 | Massachusetts General HospitalOTHER | 1 | Nov 22, 2022 | clinicaltrials |
| NCT03798769 | Supportive Oncology Care at Home for Patients With Pancreatic Cancer Receiving Preoperative FOLFIRINOX | completed | N/A | 60 | Massachusetts General HospitalOTHER | 1 | Nov 22, 2022 | clinicaltrials |
| NCT05226572 | Repeated EUS-guided Fine Needle Biopsy of Pancreatic Masses After Non-diagnostic or Inconclusive Results(REuBio) | completed | — | 462 | University of BolognaOTHER | 1 | Nov 8, 2022 | clinicaltrials |
| NCT02428270 | A Study of GSK2256098 and Trametinib in Advanced Pancreatic Cancer | completed | Phase 2 | 16 | University Health Network, TorontoOTHER | 1 | Nov 1, 2022 | clinicaltrials |
| NCT05266300 | Implementation and Quality Assurance of DPYD-genotyping in Patients Treated With Fluoropyrimidines. | completed | — | 722 | University of Southern DenmarkOTHER | 1 | Nov 1, 2022 | clinicaltrials |
| NCT01926197 | Phase 3 Study of FOLFIRINOX (mFFX) +/- SBRT in Locally Advanced Pancreatic Cancer | completed | Phase 3 | 27 | Stanford UniversityOTHER | 2 | Oct 28, 2022 | clinicaltrials |
| NCT02830620 | Study at the Man of the Profile of Chimiokines in the Anorexia Bound to the Cancerous Cachexy(CHIMIOKINES) | completed | N/A | 40 | Centre Hospitalier Universitaire de NiceOTHER | 1 | Oct 26, 2022 | clinicaltrials |
| NCT02562716 | S1505: Combination Chemotherapy or Gemcitabine Hydrochloride and Paclitaxel Albumin-Stabilized Nanoparticle Formulation Before Surgery in Treating Patients With Pancreatic Cancer That Can Be Removed by Surgery | completed | Phase 2 | 147 | SWOG Cancer Research NetworkNETWORK | 1 | Oct 19, 2022 | clinicaltrials |
| NCT03665441 | Study of Eryaspase in Combination With Chemotherapy Versus Chemotherapy Alone as 2nd-Line Treatment in PAC(Trybeca-1) | completed | Phase 3 | 512 | ERYtech PharmaINDUSTRY | 3 | Oct 18, 2022 | clinicaltrials |
| NCT05305001 | Germline Mutations Associated With Hereditary Pancreatic Cancer in Unselected Patients With Pancreatic Cancer in Mexico | completed | — | 107 | Instituto Nacional de Ciencias Medicas y Nutricion Salvador ZubiranOTHER | 1 | Oct 18, 2022 | clinicaltrials |
| NCT02489422 | Programs To Support You During Chemotherapy(PRO-YOU) | completed | N/A | 44 | Wake Forest University Health SciencesOTHER | 1 | Oct 14, 2022 | clinicaltrials |
Data updated 23 days agoSource updated May 15, 2023source: clinicaltrials